Verantos, Lundbeck partner on using advanced RWE to boost migraine care


Study will implement AI-powered technology approaches in support of migraine therapy

Verantos, a provider of electronic health record (EHR)-based studies for regulatory and reimbursement use, has struck a partnership with Lundbeck, a biopharma company that develops therapies for brain diseases. The companies will collaborate on a study to enable real-world evidence (RWE) to assist with migraine therapy.

The May announcement comes during both mental health and brain tumor awareness month, which will be followed by migraine awareness month in June. Studies have connected migraines with mental health issues and brain tumors. For example, the Journal of Neurology, Neurosurgery & Psychiatry (AJMC) notes that those with chronic migraines are twice as likely to suffer from depression and anxiety than those with less frequent migraines. In addition, migraines are one of the most common initial symptoms of brain tumors, according to a nationwide population-based study published in AJMC.

Customarily, migraine has been a challenge to study and treat with the use of real-world data due to the challenge that identifying patient characteristics entails accurately. Keeping this in mind, advanced RWE uses artificial intelligence (AI)-powered deep phenotyping and linked outcomes to understand disease progression and treatment effectiveness.

“We are delighted to collaborate with Lundbeck in their advanced RWE program,” said Dan Riskin, MD, CEO of Verantos. “Using routinely collected data to enable tailored therapy pushes the boundaries of neuroscience and demonstrates Lundbeck’s commitment to innovation and patient centricity.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.